hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06310434 id: PI23/00409 briefTitle: Analysis of COMPASsion and Humanisation of Adolescents Facing the End-of-life Processes. acronym: COMPAS overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-12 date: 2026-12 date: 2024-03-15 date: 2024-03-19 name: Instituto de Salud Carlos III class: OTHER_GOV briefSummary: The investigators want to work on compassion, understood as the recognition of the suffering of others that motivates us to try to alleviate it. The goal of this Multicenter project, with a mixed sequential transformative methodology, is to analyze the impact of a participatory process of awareness and reflection on compassion, in the face of end-of-life processes, in adolescents aged 12-23 years in 6 Spanish provinces, and to understand how the participatory process can transform and improve their compassion.
With this project, the investigators will empower new generations of people to encourage, facilitate, support, and celebrate mutual care and family and community development in end-of-life processes. The translation and implications of the results for clinical practice will contribute to reducing inequalities in health research in a vulnerable group of special interest, especially when treatments can do nothing for their survival but with interventions such as those in this study, the investigators can ensure quality and dignity of life as long as there is life. conditions: Compassion conditions: Death Anxiety conditions: Adolescent Behavior studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1852 type: ESTIMATED name: questionnaire name: Discussion group name: Reflective diary measure: Describe and improve the level of compassion of high school and university students. measure: Describe and improve the attitude towards death of high school and university students. sex: ALL minimumAge: 12 Years maximumAge: 23 Years stdAges: CHILD stdAges: ADULT facility: Instituto Murciano de Investigación Biosanitaria city: Murcia state: MU zip: 30120 country: Spain name: Eva Abad-Corpa, PhD role: CONTACT email: eva.abad@um.es name: Miriam Espinosa-Sánchez, MhD role: CONTACT email: miriam.espinosa1@um.es lat: 37.98704 lon: -1.13004 hasResults: False
nctId: NCT06310421 id: Screening_SMA briefTitle: Spinal Muscular Atrophy Neonatal Screening Program overallStatus: RECRUITING date: 2023-10-16 date: 2026-05-31 date: 2026-05-31 date: 2024-03-15 date: 2024-03-18 name: IRCCS Burlo Garofolo class: OTHER briefSummary: Spinal muscular atrophy (SMA) is a group of disorders caused by the degeneration of the motor neuron cells of the anterior horn of the spinal cord and, in some subtypes, of the bulbar motor neurons. Almost all cases are genetically determined. Most SMAs are autosomal recessive diseases, caused by homozygous deletions of the survival motor neuron (SMN) gene located on the long arm of chromosome 5. The estimated incidence of recessive childhood and juvenile SMA linked to deletion of the SMN gene is 1 in 6000 to 10000 live births, with a carrier frequency of 1 in 35 in the general population, making it a major genetic cause of infant mortality. Up to 95-97% of all childhood cases are due to homozygous deletions of the survival motor neuron 1 (SMN1) gene, or telomeric SMN, located on chromosome 5q11.2-13.3. The remaining 3-5% of cases are due to small mutations in SMN1 (rather than complete deletions).
Until a few years ago, the prognosis of type 1 SMA was poor. In the absence of therapies, the only measures were supportive (ventilation, nutrition) and the prospect, especially in the early forms, was to accompany them towards an early end of life. There are currently three treatment options available: nusinersen, risdiplam, and gene therapy with onasemnogene abeparvovec. The three options were found to be equally effective in reducing the symptoms of the disease, making it possible to reach or safeguard fundamental stages in a child's neuromotor development, starting from the ability to remain seated. At this moment, gene therapy is probably the preferred choice. To date, in Italy, there are approximately 100 patients undergoing gene therapy.
To ensure maximum benefit for affected patients, it is essential that the therapy is administered as soon as possible. Literature shows how the administration of gene therapy in pre-symptomatic subjects made it possible to achieve a better neurological outcome compared to symptomatic patients. From this perspective, the inclusion of spinal muscular atrophy in neonatal screening is of fundamental relevance. conditions: Spinal Muscular Atrophy studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: PROSPECTIVE count: 11500 type: ESTIMATED name: Screening SMA test measure: Rate of newborn screened sex: ALL minimumAge: 48 Hours maximumAge: 72 Hours stdAges: CHILD facility: SC Pediatria Gorizia - Monfalcone status: RECRUITING city: Monfalcone state: Gorizia country: Italy name: Danica Dragovic, MD role: CONTACT phone: +39 0481 487252 email: danica.dragovic@asugi.sanita.fvg.it lat: 45.80463 lon: 13.53292 facility: Institute for Maternal and Child Health - IRCCS "Burlo Garofolo" status: RECRUITING city: Trieste zip: 34137 country: Italy name: Sheila Ulivi, MSc role: CONTACT phone: +36.040 3785 226 email: sheila.ulivi@burlo.trieste.it name: Luca Ronfani, PhD MD role: CONTACT phone: +39.040.3785.297 email: luca.ronfani@burlo.trieste.it lat: 45.64953 lon: 13.77679 hasResults: False
nctId: NCT06310408 id: 0214022024 briefTitle: Comparison Between Nasal Mask vs Nasal Prong on Pain Response in Neonate overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2024-06-01 date: 2024-06-01 date: 2024-03-15 date: 2024-03-15 name: Indonesia University class: OTHER briefSummary: to determine the comparison of nasal masks and nasal prongs on the pain response of neonate conditions: Nasal Mask conditions: Nasal Prong studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1 group give nasal mask
nctId: NCT06310395 id: AMI_H.MAR briefTitle: Analysis of the Acute Mesenteric Ischemia in a Single Institution Over 10 Years acronym: AMI_HMAR overallStatus: NOT_YET_RECRUITING date: 2024-06-15 date: 2024-07-15 date: 2024-10-15 date: 2024-03-15 date: 2024-03-15 name: Hospital del Mar class: OTHER briefSummary: Acute mesenteric ischemia (AMI) is a notorious disease with a high mortality, the diagnostic and management is truly multidisciplinary, and the aim of this study is to analyse the results of the patients admited with an AMI in Hospital de Mar. conditions: Acute Mesenteric Ischemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED measure: Mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06310382 id: GH55-CRS001 briefTitle: A Phase I/II Clinical Study to Evaluate The Safety, PK, PD of GH55 in Patients With MAPK Mutant Advanced Solid Tumors overallStatus: RECRUITING date: 2022-12-07 date: 2025-05-26 date: 2025-08-04 date: 2024-03-15 date: 2024-03-18 name: Suzhou Genhouse Bio Co., Ltd. class: OTHER name: Shanghai East Hospital name: Shandong Tumor Hospital briefSummary: This is a multi-center, open-label, dose escalation phase I and dose expansion phase II study aimed to evaluate the safety, tolerability, PK and PD profiles as well as to observe the efficacy of GH55 in patients with MAPK mutant advanced solid tumors.
This study is divided into two parts, namely the dose escalation phase I study and the dose expansion phase II study. conditions: Advanced Solid Tumors With MAPK Signal Pathway Mutant studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 110 type: ESTIMATED name: GH55 measure: Number of participants with dose limiting toxicities measure: Number of participants with adverse events measure: Objective response rate (ORR) measure: Progression-free survival (PFS) measure: Duration of response (DOR) measure: Progression-free survival (PFS) measure: Number of participants with adverse events measure: Plasma concentration (Cmax) measure: Time to achieve Cmax (Tmax) measure: Area under the plasma concentration-time curve (AUC) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai East Hospital status: RECRUITING city: Shanghai state: Shanghai zip: 200120 country: China name: JIN LI, DOCTORATE role: CONTACT phone: 021-38804518 email: lijin@csco.org.cn lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06310369 id: EORTC 2335-GUCG briefTitle: Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer overallStatus: NOT_YET_RECRUITING date: 2025-03-01 date: 2025-10-01 date: 2030-03-01 date: 2024-03-15 date: 2024-03-15 name: European Organisation for Research and Treatment of Cancer - EORTC class: NETWORK briefSummary: We aim to investigate a possible role for radiotherapy in good prognosis bladder cancer patients has been identified as a possible alternative to cystectomy, especially for patients non-eligible for surgery but has yet to be fully explored. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: radiation therapy measure: Proportion of patients with a CR at 6 months post-radiotherapy measure: Progression-free survival measure: overall survival sex: MALE minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06310343 id: 304993 briefTitle: ADAs to Alemtuzumab overallStatus: ACTIVE_NOT_RECRUITING date: 2022-04-25 date: 2025-11-30 date: 2025-11-30 date: 2024-03-15 date: 2024-03-15 name: Queen Mary University of London class: OTHER briefSummary: The main aim is to quantify the changes in alemtuzumab antibody-anti-alemtuzumab over a 24 months period conditions: Multiple Sclerosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 15 type: ACTUAL name: Alemtuzumab measure: To quantify the longitudinal changes in alemtuzumab ADAs measure: 1. Relative occurrence of infusion-related reactions based on high alemtuzumab ADA levels prior to course 2. measure: 2. Relative change in lymphocyte counts after the second infusion of alemtuzumab in ADA positive patients to assess the health economic impact of infusion-related reactions. measure: 3. Relative change in relapses or EDSS score based on alemtuzumab ADA levels to assess the health economic impact of disease activity. measure: 4. Relative change in relapses or EDSS score based on alemtuzumab ADA levels measure: 5. Relative change in T2 lesion number or Gd-enhancing lesions, and serum NfL based on alemtuzumab ADA levels to assess the health economic impact of disease activity. sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Barts Health NHS Trust city: London state: Second Floor Neurophys Dept country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06310330 id: 2019/1059 briefTitle: TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography acronym: TRUST-ACE overallStatus: RECRUITING date: 2024-03-08 date: 2026-12-31 date: 2026-12-31 date: 2024-03-15 date: 2024-03-20 name: Norwegian University of Science and Technology class: OTHER name: St. Olavs Hospital briefSummary: TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD).
Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice. conditions: Breast Neoplasm Malignant Primary studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomization 1:1 to two different modes of follow-up primaryPurpose: DIAGNOSTIC masking: NONE maskingDescription: No masking count: 250 type: ESTIMATED name: Comprehensive echocardiographic follow-up name: Simplified echocardiographic follow-up measure: Proportion of patients correctly classified with cancer therapy related cardiac dysfunction (CTRCD) measure: Proportion of patients misclassified as having/not having cancer therapy related cardiac dysfunction (CTRCD) measure: Risk classification measure: Risk classification measure: Test-retest variability, systolic left ventricular size and function measure: Test-retest variability, systolic left ventricular size and function measure: Test-retest variability, diastolic left ventricular size and function measure: Test-retest variability, diastolic left ventricular size and function measure: Test-retest variability, right ventricular size and function measure: Test-retest variability, right ventricular size and function measure: Time consumption measure: Time consumption sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St. Olavs hospital status: RECRUITING city: Trondheim zip: 7491 country: Norway name: Rune Wiseth, MD, PhD role: CONTACT phone: 92247845 phoneExt: 47 email: rune.wiseth@stolav.no lat: 63.43049 lon: 10.39506 hasResults: False
nctId: NCT06310317 id: CNR-IRIB-PRO-2024-003 briefTitle: Applied Behavior Analysis With Technologies overallStatus: RECRUITING date: 2023-09-01 date: 2025-01-31 date: 2025-01-31 date: 2024-03-15 date: 2024-03-15 name: Istituto per la Ricerca e l'Innovazione Biomedica class: OTHER briefSummary: Applied Behavior Analysis (ABA) is a therapeutic approach for autism that is based on the principles of behavioral theory, learning, and positive reinforcement. Current research shows that early and intensive ABA intervention is effective in reducing dysfunctional behaviors and promoting learning and enactment of socially appropriate behaviors.
In this context, new approaches that attempt to integrate advanced technologies can play a key role. This experimental protocol aims to test whether the use of advanced technologies, such as tablets, as part of an intervention for a group of children with autism spectrum disorder (ASD) is more effective than the traditional approach implemented in a control group of children with ASD. The experimental protocol is aimed at enhancing cognitive skills, increasing new skills and acquiring functional/adaptive behaviors. conditions: Autism conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: Applied Behavior Analysis protocol name: Traditional intervention measure: Verbal Behavior Milestones Assessment and Placement Program (VB-MAPP) sex: ALL minimumAge: 5 Years maximumAge: 12 Years stdAges: CHILD facility: Institute for Biomedical Research and Innovation (IRIB) - National Research Council (CNR) status: RECRUITING city: Messina zip: 98164 country: Italy name: Flavia Marino role: CONTACT phone: +393395798263 email: flavia.marino@irib.cnr.it name: Maria Valeria Maiorana role: CONTACT phone: +393285856656 email: mariavaleria.maiorana@irib.cnr.it name: Flavia Marino role: PRINCIPAL_INVESTIGATOR name: Giovanni Pioggia role: SUB_INVESTIGATOR name: Paola Chilà role: SUB_INVESTIGATOR name: Roberta Minutoli role: SUB_INVESTIGATOR name: Noemi Vetrano role: SUB_INVESTIGATOR name: Chiara Failla role: SUB_INVESTIGATOR name: Germana Doria role: SUB_INVESTIGATOR name: Ileana Scarcella role: SUB_INVESTIGATOR name: Cinzia Grasso role: SUB_INVESTIGATOR name: Mariaelena Franchina role: SUB_INVESTIGATOR lat: 38.19394 lon: 15.55256 hasResults: False
nctId: NCT06310304 id: INCB18424-153 briefTitle: A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants. overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-26 date: 2024-04-16 date: 2024-05-15 date: 2024-03-15 date: 2024-04-10 name: Incyte Corporation class: INDUSTRY briefSummary: This study is conducted to determine the Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 24 type: ACTUAL name: Ruxolitinib IR name: Ruxolitinib XR measure: INCB018424 pharmacokinetic (PK) in Plasma measure: Number of participants with Treatment Emergent Adverse Events (TEAEs) measure: Additional INCB018424 pharmacokinetic (PK) in Plasma sex: ALL minimumAge: 19 Years maximumAge: 55 Years stdAges: ADULT facility: Celerion, Inc city: Lincoln state: Nebraska zip: 68502 country: United States lat: 40.8 lon: -96.66696 hasResults: False
nctId: NCT06310278 id: 1030312 briefTitle: Ossiview Normative Mobility Data Collection Protocol overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-10-31 date: 2024-10-31 date: 2024-03-15 date: 2024-03-15 name: Audioptics Medical Incorporated class: INDUSTRY briefSummary: The goal of this observational study is to learn about the sound-induced vibration level of certain structures in the middle ear in the normal-hearing population. The targeted structures are part of a chain of structures responsible for conducting sound within the auditory system and so their ability to vibrate normally in response to sound is relevant to the diagnosis of conductive hearing loss.
Participants will have their ossicular mobility measured with an investigational medical device that sends light into the middle ear and measures the motion-induced phase shift on light reflected from the target structures when a sound stimulus is presented. Standard hearing tests including audiometry and tympanometry will also be performed to confirm the normal hearing status of participants. conditions: Conductive Hearing Loss, Middle Ear studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: Ossicular mobility measurement measure: Umbo mobility measure: Incus mobility measure: Dependence on age and sex sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06310265 id: TABED 1-24-21 briefTitle: Our Anesthesia Experiment Applied to Child Earthquake Victims in the February 6, 2023 Earthquake overallStatus: RECRUITING date: 2024-03-12 date: 2024-04-05 date: 2024-04-22 date: 2024-03-15 date: 2024-04-19 name: Ankara City Hospital Bilkent class: OTHER briefSummary: The study aimed to investigate anesthesia management of pediatric patients in the Ankara Bilkent City Hospital during the earthquake disaster of February 6. conditions: Earthquake conditions: Crush Injury conditions: Anesthesia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 50 type: ESTIMATED name: Retrospective observational study measure: The anesthesia management under pediatric earthquake victims sex: ALL minimumAge: 30 Days maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Ankara Bilkent City Hospital status: RECRUITING city: Ankara zip: 06800 country: Turkey name: Sengul Ozmert role: CONTACT phone: +905323861201 email: sengulozmert@yahoo.com.tr lat: 39.91987 lon: 32.85427 facility: Ankara Bilkent City Hospital,Department Of Anesthesiology and Reanimation status: RECRUITING city: Ankara state: Çankaya zip: 06800 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06310252 id: PRO_010-2023 briefTitle: Safety and Efficacy of an Intrastromal Transform Corneal Allograft (TCA) for Presbyopia Correction - Long Term Follow-up overallStatus: RECRUITING date: 2024-02-13 date: 2024-06 date: 2024-09 date: 2024-03-15 date: 2024-03-15 name: Allotex, Inc. class: INDUSTRY briefSummary: The objective of this clinical study is to evaluate the long term safety and effectiveness of intrastromal implantation of the Allotex TransForm corneal allograft (TCA) for providing near vision in presbyopic subjects.
A maximum of 101 eyes of qualified and consented subjects will undergo long term follow-up after instrastromal implantation of the TCA for presbyopia. conditions: Presbyopia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 101 type: ESTIMATED name: Opthalmic assessments measure: An exploratory data collection project with no primary safety or effectiveness endpoints. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Gemini - Oční klinika Zlín status: RECRUITING city: Zlín zip: 760 01 country: Czechia name: Stodůlka role: CONTACT phone: +420 577 202 202 email: info@gemini.cz lat: 49.22645 lon: 17.67065 facility: Wellington Eye Clinic status: NOT_YET_RECRUITING city: Dublin zip: D18 T8P3 country: Ireland lat: 53.33306 lon: -6.24889 facility: Medipol University status: RECRUITING city: Istanbul zip: 34214 country: Turkey name: Tanriverdi role: CONTACT phone: +904447044 email: international@medipol.com.tr lat: 41.01384 lon: 28.94966 facility: Centre For Sight status: NOT_YET_RECRUITING city: East Grinstead zip: RH149 4RH country: United Kingdom lat: 51.12382 lon: -0.0061 hasResults: False
nctId: NCT06310226 id: 23-000347 briefTitle: Phenotyping Response to Spinal Cord Stimulation in Chronic Low Back Pain overallStatus: RECRUITING date: 2024-04-01 date: 2025-03-01 date: 2025-03-01 date: 2024-03-15 date: 2024-03-15 name: University of California, Los Angeles class: OTHER briefSummary: Chronic low back pain (CLBP) is a debilitating condition and costly to treat. Long-term drug treatment often fails due to habituation, breakthrough of pain, or adverse effects of drug treatment. Opioid use to manage this pain has contributed to the opioid epidemic. Spinal cord stimulators have emerged as a promising treatment and reduces reliance on drugs. However, response to spinal cord stimulation (SCS) is unpredictable. It is difficult to predict which patients will respond positively to SCS because the physiological mechanism for treatment responsiveness is unclear. Therefore, the aim of this study is to investigate how spinal cord stimulators affect functional measures in patients with CLBP, including functional MRI, neurophysiology, gait analysis, and questionnaires. The results of this study can lead to the widespread adoption of spinal cord stimulators as a safe and effective therapy for CLBP, reducing the reliance on opioids and mitigating the opioid epidemic's impact. conditions: Chronic Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 20 type: ESTIMATED name: Epidural electrical spinal cord stimulator measure: Detection of brain connectivity using functional MRI measure: Detection of brain waves using electroencephalography (EEG) measure: Neurological gait kinematics assessment measure: Neurophysiological functional assessment using somatosensory evoked potential (SSEP) measure: Neurophysiological functional assessment using pain-related evoked potential (PREP) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California, Los Angeles status: RECRUITING city: Los Angeles state: California zip: 90095 country: United States name: Chau role: CONTACT lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06310213 id: 17368 briefTitle: Non-Invasive Pressure Monitor for Neonates & Infants at Risk of Developing Hydrocephalus overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2028-06-01 date: 2028-07-01 date: 2024-03-15 date: 2024-03-15 name: Indiana University class: OTHER briefSummary: The goal of this clinical trial is to test a modified smart soft contact lens in neonates and infants at risk of developing hydrocephalus. The main questions it aims to answer are: